BAC vs MRNA Stock Comparison

MRNA currently leads BAC in this stock comparison, with AIQ scores of 63 vs 58. The clearest difference is momentum, while BAC has the stronger risk resilience profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 5 points
BAC
Financial Services
vs
MRNA
Healthcare
BAC
Bank of America Corporation
Price
$51.02
Day move
+1.01%
AIQ Score
58/100
Best edge
Risk Resilience
Sector
Financial Services
MRNA
Moderna, Inc.
Leads
Price
$223
Day move
-3.45%
AIQ Score
63/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between BAC and MRNA?

MRNA leads the current stock comparison as Moderna, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Bank of America Corporation vs Moderna, Inc.

Data as of Nov 15, 2026· market close· Cross-sector · Financial Services vs Healthcare· Coverage 66/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 3/10

MRNA leads

MRNA leads by 5 AIQ points, primarily on Momentum, and the lead has widened from 2 points over 30 sessions. Wall Street currently favors BAC on target upside.

Fragile: 2 of 6 evidence groups support MRNA, its lead is widening, and its current signal state is conflicted.

Evidence agreement: 2 of 6Comparison trend: Strengthening
BAC

Bank of America Corporation

AIQ Score
58/100
AIQ Edge Score
6/10
MRNA

Moderna, Inc.

Leads
AIQ Score
63/100
AIQ Edge Score
7/10

The Algovestiq AIQ Score currently favors MRNA over BAC, 63 versus 58 as of Nov 15, 2026. MRNA's advantage is driven primarily by stronger momentum, while BAC holds the stronger risk resilience profile. MRNA also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors BAC. 2 of 6 covered evidence groups favor MRNA today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 5 points. MRNA lead: Strengthening — the AIQ differential moved from 2 to 5 points over 30 sessions.

Compare Bank of America Corporation and Moderna, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Total return with distributions reinvested, from daily closes.

BAC
+24.0%
MRNA
-7.8%

Total return comparison

Growth of $10,000, distributions reinvested

BAC $12,399 · MRNA $9,221

Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.

Compare BAC and MRNA against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

BAC advantage
0
MRNA advantage
  • Momentum37 vs 93
    MRNA +56
  • Risk Resilience83 vs 31
    BAC +52
  • Value68 vs 50
    BAC +18
  • Quality64 vs 52
    BAC +12

2 of 6 evidence groups favor MRNA. MRNA’s edge is concentrated in momentum; BAC keeps a meaningful risk resilience edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

BAC0 AIQ

No factor moved materially.

New signals

  • OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)
MRNA0 AIQ

Largest factor move: Quality +1, not enough on its own to move the overall score.

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.54x)
  • RSI Midline Rejection — bearish, momentum, short horizon

MRNA's lead was unchanged in the latest session.

Deeper signal detail for each name lives on its own signals page — BAC and MRNA both carry a full feed there.

The central trade-off

MRNA (Moderna, Inc.): the stronger current systematic profile, led by momentum.

BAC (Bank of America Corporation): the counter-case, on risk resilience, value, quality.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

MRNA

MRNA on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

MRNA

MRNA on combined revenue and EPS growth.

Value

BAC

BAC on the peer-relative Value factor, by 18 points.

Momentum

MRNA

MRNA on the Momentum factor, by 56 points.

Lower downside

BAC

BAC on Risk Resilience, by 52 points.

Analyst upside

BAC

BAC on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors MRNA, analyst targets favor BAC. That disagreement is the most useful thing on this page.

MeasureBACMRNANote
Implied upside to target+24.1%-22.5%BAC has more room
Target dispersion+25.3%+129.4%Lower is tighter analyst agreement
ConsensusBuyHoldContext, not a primary driver
Analysts covering2524Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

2 of 6 covered evidence groups favor MRNA. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreMRNA58 vs 63
FundamentalsEvenrevenue growth -3.3% vs 8.1%; EPS growth -23.8% vs 120.4%; TTM ROE 2.3% vs 2.4%; gross margin 60.4% vs 28%; operating margin 22.4% vs -116%
ValuationBACValue 68 vs 50
TechnicalsMRNAPrice vs 50-day -5.6% vs 10.8%; vs 200-day -7% vs 131.7%
Risk ResilienceBACRisk Resilience 83 vs 31
Analyst expectationsBACTarget upside 24.1% vs -22.5%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BAC and MRNA and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is narrow at 5 points. (argues the conclusion is provisional)
  • Only 2 of 6 covered evidence groups agree. (argues the conclusion is provisional)
  • The leader's advantage has been widening. (supports the conclusion holding)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)
  • Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on MRNA.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

MRNA lead: Strengthening — the AIQ differential moved from 2 to 5 points over 30 sessions.

May 27BAC leads above the line · MRNA leads belowNov 13
Today
MRNA +5
58 vs 63
7 sessions ago
MRNA +5
58 vs 63
30 sessions ago
MRNA +2
62 vs 64
90 sessions ago
BAC +8
71 vs 63

The lead changed hands 2 times in this window, most recently on Jun 24 when MRNA moved ahead of BAC.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

BACConflicted

2 bullish / 2 bearish / 1 neutral, conflicted

Only BAC

  • Bollinger Band Squeeze — neutral, volatility, short horizon (4.5%)
  • Death Cross Active — bearish, trend, long horizon (1.45%)
  • Downtrend Structure Active — bearish, trend, long horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)
MRNAConflicted

3 bullish / 4 bearish / 1 neutral, conflicted

Only MRNA

  • Golden Cross Active — bullish, trend, long horizon (109.17%)
  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (8.88%)
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.54x)
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
  • RSI Midline Rejection — bearish, momentum, short horizon
  • Uptrend Structure Active — bullish, trend, long horizon

MRNA leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

BACNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.01%, AIQ 0 points).

MRNANo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -3.45%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1BAC closes the Momentum gap — currently 56 points behind, the largest single contributor to MRNA's edge.
  2. 2BAC's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3MRNA's conflicting signal state resolves bearish — it currently carries 3 bullish and 4 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

Split
MetricBACMRNA
Revenue growth (YoY)-3.3%8.1%
EPS growth (YoY)-23.8%120.4%
Gross margin60.4%28%
Operating margin22.4%-116%
Return on equity (TTM)2.3%2.4%
Debt to equity1.280.61

Performance

MRNA leads 5 of 6 windows
MetricBACMRNA
1 week (5 sessions)3.2%-12.1%
1 month (20 sessions)-0.4%2.5%
3 months (63 sessions)-20.1%246.5%
6 months (126 sessions)2.5%355.5%
Year to date-7.2%657.4%
1 year (252 sessions)-5.7%736.3%

Technicals

MRNA has the stronger structure
MetricBACMRNA
RSI (14)45.949.7
ADX (14)27.235.6
Price vs 50-day-5.6%10.8%
Price vs 200-day-7%131.7%
Volatility (1M, annualized)24.8%103.9%

Risk

BAC is the more resilient
MetricBACMRNA
Beta0.792.33
Sharpe ratio-0.221.67
Sortino ratio-0.296.38
Max drawdown-23.7%-34.2%
Current drawdown-21.3%-17%
Annualized volatility22.4%194.6%
Value at risk (95%)-2.6%-7%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, BAC or MRNA?

On the Algovestiq AIQ Score, MRNA is the stronger of the two as of Nov 15, 2026, scoring 63 against BAC's 58. The edge comes from momentum. BAC is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is BAC or MRNA the better buy right now?

MRNA carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 5 points. Treat the lead as provisional.

Why does the AIQ Score favor MRNA over BAC?

The composite weights Quality, Value, Momentum and Risk Resilience. MRNA leads Momentum by 56 points; BAC leads Risk Resilience by 52 points; BAC leads Value by 18 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, BAC or MRNA?

Analyst price targets imply +24.1% upside for BAC and -22.5% for MRNA, so the Street currently favors BAC. That points the opposite way to the AIQ Score, which favors MRNA. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, BAC or MRNA?

BAC is the better-valued of the two on the peer-relative Value factor. BAC on the peer-relative Value factor, by 18 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, BAC or MRNA?

MRNA on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, BAC or MRNA?

MRNA on the Momentum factor, by 56 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, BAC or MRNA?

BAC is the more resilient of the two, so the other name carries the higher downside risk. BAC on Risk Resilience, by 52 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is BAC more profitable than MRNA?

BAC leads on the comparable margin measures — gross margin 60.4% vs 28%; operating margin 22.4% vs -116%; ttm roe 2.3% vs 2.4%.

Is MRNA's lead over BAC getting stronger or weaker?

MRNA lead: Strengthening — the AIQ differential moved from 2 to 5 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 2 times in that window, most recently on 2026-06-24, when MRNA moved ahead of BAC.

What would change the BAC vs MRNA verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BAC closes the Momentum gap — currently 56 points behind, the largest single contributor to MRNA's edge; BAC's Death Cross Active resolves — a bearish trend rule currently active against it; MRNA's conflicting signal state resolves bearish — it currently carries 3 bullish and 4 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about BAC and MRNA?

BAC: 2 bullish / 2 bearish / 1 neutral, conflicted. MRNA: 3 bullish / 4 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BAC is Death Cross Active (bearish, long horizon). On MRNA it is Golden Cross Active (bullish, long horizon).

Compare BAC and MRNA with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.